[HTML] mdpi.com

[HTML][HTML] Serum cystatin C as a biomarker for early diabetic kidney disease and dyslipidemia in young type 1 diabetes patients

I Stankute, L Radzeviciene, A Monstaviciene… - Medicina, 2022 - mdpi.com
Background and objectives: This study aimed to assess the clinical significance of serum
cystatin C in the early diagnosis of renal injury and its association with dyslipidemia in young …
被引用次数：8 相关文章

Serum cystatin C as a biomarker for early diabetic kidney disease and dyslipidemia in young type 1 diabetes patients

I Stankutė, L Radzevičienė, A Monstavičienė… - … MDPI, 2022, vol. 58, no. 2, 2022 - lsmu.lt
Background and objectives: This study aimed to assess the clinical significance of serum
cystatin C in the early diagnosis of renal injury and its association with dyslipidemia in young …
[HTML] nih.gov

[HTML][HTML] Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients

I Stankute, L Radzeviciene, A Monstaviciene… - Medicina, 2022 - ncbi.nlm.nih.gov
Background and objectives: This study aimed to assess the clinical significance of serum
cystatin C in the early diagnosis of renal injury and its association with dyslipidemia in young …

Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients

I Stankute, L Radzeviciene… - Medicina (Kaunas …, 2022 - pubmed.ncbi.nlm.nih.gov
Background and objectives: This study aimed to assess the clinical significance of serum
cystatin C in the early diagnosis of renal injury and its association with dyslipidemia in young …

Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients

I Stankute, L Radzeviciene, A Monstaviciene… - Medicina, 2022 - search.proquest.com
Background and objectives: This study aimed to assess the clinical significance of serum
cystatin C in the early diagnosis of renal injury and its association with dyslipidemia in young …

Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients.

I Stankute, L Radzeviciene… - Medicina …, 2022 - search.ebscohost.com
Background and objectives: This study aimed to assess the clinical significance of serum
cystatin C in the early diagnosis of renal injury and its association with dyslipidemia in young …

Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients.

I Stankute, L Radzeviciene… - Medicina (Kaunas …, 2022 - europepmc.org
Background and objectives: This study aimed to assess the clinical significance of serum
cystatin C in the early diagnosis of renal injury and its association with dyslipidemia in young …
[PDF] semanticscholar.org

[PDF][PDF] Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients

I Stankute, L Radzeviciene, A Monstaviciene… - …, 2022 - pdfs.semanticscholar.org
Background and objectives: This study aimed to assess the clinical significance of serum
cystatin C in the early diagnosis of renal injury and its association with dyslipidemia in young …

Serum Cystatin C as a Biomarker for Early Diabetic Kidney Disease and Dyslipidemia in Young Type 1 Diabetes Patients.

I Stankute, L Radzeviciene… - Medicina (Kaunas …, 2022 - europepmc.org
Background and objectives: This study aimed to assess the clinical significance of serum
cystatin C in the early diagnosis of renal injury and its association with dyslipidemia in young …